<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386097</url>
  </required_header>
  <id_info>
    <org_study_id>DiabetesIC2</org_study_id>
    <nct_id>NCT03386097</nct_id>
  </id_info>
  <brief_title>Interstitial Fluid in the Development of Cardiovascular Disease</brief_title>
  <official_title>Studies of the Importance of Interstitial Fluid in the Development of Cardiovascular Disease, an Expanded Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      At a given level of serum cholesterol, patients with T2D have an increased risk of developing&#xD;
      atherosclerosis compared with nondiabetic subjects.&#xD;
&#xD;
      In a previous study we showed that the interstitial fluid-to-serum gradient of LDL and VLDL&#xD;
      cholesterol is reduced in T2D patients compared with healthy controls. This was not found for&#xD;
      HDL cholesterol. However, the cholesterol transporting function of HDL particles from&#xD;
      interstitial fluid from patients with T2D were lower than in healthy controls. We hypothesize&#xD;
      that that the apo B-containing particles in T2D patients are more susceptible to be retained&#xD;
      or consumed in the extravascular space.&#xD;
&#xD;
      We are to study if skin biopsies from T2D patients contain more cholesterol than biopsies&#xD;
      from healthy controls. We hypothesize that samples from T2D patients are richer in&#xD;
      cholesterol, which could explain why VLDL and LDL cholesterol are lower in relation to their&#xD;
      plasma levels in T2D.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2018</start_date>
  <completion_date type="Actual">September 3, 2021</completion_date>
  <primary_completion_date type="Actual">September 3, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Interstitial fluid-to-serum ratio for LDL cholesterol</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cholesterol level in skin biopsies</measure>
    <time_frame>30 minutes</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Type2 Diabetes</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Type 2 diabetes patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of interstitial fluid, skin biopsies and blood</intervention_name>
    <description>Collection of interstitial fluid, skin biopsies and blood</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Type 2 diabetes patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Interstitial fluid, skin biopsies and blood (serum, plasma and whole blood)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy controls and type 2 diabetes patients over 18 years old, matched for age and&#xD;
        gender.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Over 18 years.&#xD;
&#xD;
          -  For the T2D study group: Diagnosed with type 2 diabetes.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        For subjects with type 2 diabetes:&#xD;
&#xD;
          -  Systemic inflammatory disease that requires active treatment&#xD;
&#xD;
          -  Thyroid disease that requires active treatment&#xD;
&#xD;
          -  Skin disease that requires active treatment and causes significant changes in the area&#xD;
             of the skin that is to be investigated&#xD;
&#xD;
          -  Treatment with oral glucocorticoids&#xD;
&#xD;
          -  Levels of SR, TSH, T4 or Hemoglobin in the blood pronouncedly outside the reference&#xD;
             range&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
        For healthy controls:&#xD;
&#xD;
          -  Registered disease in the health declaration that requires continuous systemic&#xD;
             treatment. Exception to the above: well controlled hypertension in which case the&#xD;
             subject should not have treatment with more than one antihypertensive drug, the drug&#xD;
             must not be an alpha-blocker or beta-blocker or thiazide diuretic&#xD;
&#xD;
          -  Skin disease that requires active treatment and causes significant changes in the area&#xD;
             of the skin that is to be investigated&#xD;
&#xD;
          -  Blood pressure pronouncedly above 140/90&#xD;
&#xD;
          -  Blood test results pronouncedly outside the reference range&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mats Rudling</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ekerö Vårdcentral</name>
      <address>
        <city>Ekerö</city>
        <state>Ekerö Kommun</state>
        <zip>17831</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Patient research centre, Clinic of endocrinology, Karolinska University Hospital</name>
      <address>
        <city>Huddinge</city>
        <state>Stockholm</state>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stiftelsen Stockholms Sjukhems Husläkarmottagning</name>
      <address>
        <city>Stockholm</city>
        <zip>11219</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GIH (gymnastik och idrottshögskolan)</name>
      <address>
        <city>Stockholm</city>
        <zip>11433</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 21, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Mats Rudling</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <keyword>Cholesterol</keyword>
  <keyword>Interstitial fluid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

